BLACK BOX WARNING
- endometrial cancer risk (must add progestogen in women with intact uterus)
- cardiovascular disease and stroke (coronary artery disease, stroke)
- probable dementia in women ≥65 years
- breast cancer risk with combined estrogen-progestogen
estradiol
Brand: Estrace, Estradiol patch (Vivelle-Dot, Climara), Vagifem, Estring
⚠ BBW Beers Criteria Prototype Drug
Drug Class: estrogen
Drug Family: hormone
Subclass: 17-beta estradiol — endogenous estrogen
Organ Systems: endocrinereproductive
Mechanism of Action
Binds estrogen receptors (ERalpha and ERbeta) in the nucleus of target tissues (uterus, breast, brain, bone, cardiovascular). ER-ligand complex acts as a transcription factor activating estrogen response elements (ERE) on target gene promoters, producing tissue-specific effects on growth, differentiation, and metabolism.
estrogen receptor alpha (ERalpha)estrogen receptor beta (ERbeta)
Indications
- menopausal symptom relief (hot flashes, genitourinary syndrome of menopause)
- prevention of postmenopausal osteoporosis
- female hypogonadism
- primary ovarian insufficiency
- hormone replacement in transgender women
- atrophic vaginitis (low-dose vaginal formulations)
Contraindications
- estrogen-dependent cancers (breast, endometrial)
- undiagnosed vaginal bleeding
- thromboembolic disease history
- liver disease
- pregnancy
Adverse Effects
Common
- breast tenderness
- nausea
- bloating
- headache
- mood changes
- breakthrough bleeding
Serious
- endometrial cancer (with unopposed estrogen in women with intact uterus)
- breast cancer (long-term HRT)
- venous thromboembolism (DVT, PE)
- stroke
- cardiovascular events (WHI trial findings)
Pharmacokinetics (ADME)
| Absorption | transdermal patch avoids first-pass metabolism; oral undergoes significant first-pass hepatic metabolism |
| Distribution | 98% bound to SHBG and albumin |
| Metabolism | hepatic; extensive first-pass effect (oral); metabolized to estrone and estriol |
| Excretion | renal (conjugated metabolites) |
| Half-life | ~1 hour (IV); transdermal provides sustained levels |
| Onset | hours to days |
| Peak | varies by route |
| Duration | varies by route |
| Protein Binding | 98% (SHBG, albumin) |
| Vd | moderate |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| CYP3A4 inducers (rifampin, carbamazepine) | accelerate estrogen metabolism; reduced contraceptive efficacy | major |
| CYP3A4 inhibitors (ketoconazole) | increased estrogen levels | moderate |
| thyroid hormone | estrogen increases TBG, increasing T4 requirements in hypothyroid women on hormone replacement | moderate |
Nursing Considerations
- Always add a progestogen (e.g., medroxyprogesterone or micronized progesterone) in women with an intact uterus to prevent endometrial hyperplasia.
- Advise patients to apply transdermal patches to clean, dry, intact skin (not breasts or waistline); rotate sites and replace per schedule.
- Screen for contraindications before prescribing: family history of breast cancer, personal VTE history, smoking status.
- Educate patients that low-dose vaginal estradiol (ring, tablet) for genitourinary syndrome has minimal systemic absorption and may not require progestogen.
Clinical Pearls
- The WHI trial used oral conjugated equine estrogen ± medroxyprogesterone and showed increased risk of breast cancer, VTE, stroke, and CHD; subsequent analyses suggest transdermal estradiol with micronized progesterone may have a more favorable risk profile.
- Transdermal estradiol avoids first-pass hepatic metabolism, produces less effect on hepatic synthesis of clotting factors and inflammatory proteins, and is associated with lower VTE risk than oral estrogens.
Safety Profile
Pregnancy contraindicated
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.